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Abstract
Objective—As the utility of Child-Pugh (C-P) class is limited by the subjectivity of ascites and
encephalopathy, we evaluated a previously established objective method, the albumin-bilirubin
(ALBI) grade, as a prognosticator for yttrium-90 radioembolization (RE) treatment for patients
with hepatocellular carcinoma (HCC).
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Materials and Methods—A total of 117 patients who received RE for HCC from 2 academic
centers were reviewed and stratified by ALBI grade, C-P class, and Barcelona Clinic Liver Cancer
stage. The overall survival (OS) according to these 3 criteria was evaluated by Kaplan-Meier
survival analysis. The utilities of C-P class and ALBI grade as prognostic indicators were
compared using the log-rank test. Multivariate Cox regression analysis was performed to identify
additional predictive factors.
Results—Patients with ALBI grade 1 (n = 49) had superior OS than those with ALBI grade 2 (n
= 65) (P = 0.01). Meanwhile, no significant difference was observed in OS between C-P class A (n
= 100) and C-P class B (n = 14) (P = 0.11). For C-P class A patients, the ALBI grade (1 vs. 2) was
able to stratify 2 clear and nonoverlapping subgroups with differing OS curves (P = 0.03).

Reprints: Salma K. Jabbour, MD, Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, 195 Little Albany St,
New Brunswick, NJ 08903. jabbousk@cinj.rutgers.edu.
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Multivariate Cox regression test identified alanine transaminase, Barcelona Clinic Liver Cancer
stage, and ALBI grade as the strongest prognostic factors for OS (P < 0.10).
Conclusions—ALBI grade as a prognosticator has demonstrated clear survival discrimination
that is superior to C-P class among HCC patients treated with RE, particularly within the subgroup
of C-P class A patients. ALBI grade is useful for clinicians to make decisions as to whether RE
should be recommended to patients with HCC.
Keywords
hepatocellular carcinoma; yttrium-90 radioembolization; prognostic indicator; albumin-bilirubin
(ALBI) grade
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The clinical prognosis and therapeutic options of patients with hepatocellular carcinoma
(HCC) depends on both tumor burden and underlying hepatic dysfunction.1–3 The ChildPugh (C-P) scoring system has been widely used to measure the latter. This system was
originally proposed to assess surgical risk in patients with portal hypertension by Child and
Turcotte in 1964.4 In 1972, the score was modified by Pugh et al5 to include the current 5
parameters: albumin, bilirubin, ascites, encephalopathy, and prothrombin time or
international normalized ratio (INR). The C-P scoring system is limited due to subjectivity
of factors including ascites and encephalopathy. In medical practice, the clinical experience
ranges widely between novices and experienced health care providers, which affects the
judgment of ascites and encephalopathy.6 In addition, factors including ascites and serum
albumin levels are confounded by their interrelationship.
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Johnson and colleagues introduced a new model for liver function assessment only based on
albumin and bilirubin and termed the albumin-bilirubin (ALBI) grade. The formula for this
scoring system relies on the following equation: ALBI score = (log10 bilirubin [µmol/L] ×
0.66) + (albumin [g/L] × −0.0852). As a result, ALBI grades 1, 2, and 3 were developed as
follows: ALBI score ≤ −2.60 (ALBI grade 1), > −2.60 to ≤ −1.39 (ALBI grade 2), and >
−1.39 (ALBI grade 3).7 This simple and objective model demonstrated its usefulness for
evaluation of prognosis of HCC patients who underwent liver resection for early stage HCC
or who were treated with sorafenib in advanced stage HCC.8–10 Patients with intermediate
stage (eg, those treated with chemoembolization or radioembolization [RE]) were a small
subset of the patients included in the Johnson and colleagues study.
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RE is an effective therapy with a favorable toxicity profile in intermediate-stage and
advanced-stage HCC patients.11–15 Previous studies on the prognosis of HCC patients
receiving RE primarily focused on Okuda, C-P, Barcelona Clinic Liver Cancer (BCLC),
Cancer of the Liver Italian Program (CLIP) score, or the TNM Staging System. The present
study was designed to evaluate the prognostic value of ALBI grade in patients with HCC
undergoing RE. We hypothesized that the ALBI prognostic index would serve as a better
discriminator of overall survival (OS) for RE compared with C-P score.
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MATERIALS AND METHODS
Study Design and Eligibility Criteria
Our patient database was reviewed for patients with HCC treated with RE from June 2007 to
January 2015 at 2 separate institutes. Pretherapeutic baseline medical history, laboratory
values, treatment method and dosage, and survival were obtained retrospectively. All
patients were scheduled for routine follow-up on site every month in first 3 months then
every 3 months afterwards, including laboratory values, computed tomography/magnetic
resonance imaging, and performance status. Patients’ date of death and cause of death were
reported to the institutes. Death from noncancer cause was considered to be censored in the
survival analysis.
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Patients were selected to receive RE if they demonstrated an ECOG performance status from
0 to 3, alanine transaminase (ALT) < 400 IU/L, AST < 400 IU/L, total bilirubin < 2 mg/dL.
Two patients whose total bilirubin values were more than 2 mg/dL (2.2 and 2.6 mg/dL) also
received RE under the clinicians’ decision. Before RE delivery, multidisciplinary consensus
was reached to evaluate the patients’ conditions and make therapeutic decisions. Included
patients were not operative candidates. All patients were first-time treated with yttrium-90
resin microspheres when enrolled. This retrospective study received institutional review
board authorization and was compliant with the Health Insurance Portability and
Accountability Act.
Patients and Evaluation
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A total of 122 patients received RE, and 5 patients were excluded because of missing
baseline albumin or total bilirubin and according to the criteria introduced above. Baseline
characteristics were collected within 1 week before radiation therapy. Baseline laboratory
tests including complete blood count, liver function tests, INR, and α-fetoprotein level
(AFP) were collected. Baseline computed tomography scans of the abdomen and chest were
analyzed to evaluate tumor burden, volume, and vascular invasion. Baseline functional
performance status was evaluated according to ECOG criteria.
Radiation Treatment
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Patients were treated with resin-based microsphere beads (SIR-Spheres; Sirtex Medical,
Lane Cove, Australia) or glass microspheres loaded with yttrium-90 (TheraSpheres; MDS
Nordion, Kanata, ON, Canada). Pretreatment mesenteric angiography and technetium-99m
macroaggregated albumin scanning (99mTC-MAA) were performed before RE to assess for
gastrointestinal arterial supply (with identification of anatomic variants and prophylactic
embolization of vessels if necessary) and for lung shunting. RE was performed 2 to 4 weeks
following 99mTC-MAA scan using the methods outlined by Salem and Thurston.16 Resinbased yttrium-90 microspheres were dosed based on tumor volumetry and total body surface
area (BSA): activity (GBq) = (BSA − 0.2) + tumor volume/total liver volume, where BSA
(m2) = 0.20247 × height (m)0.725 × weight (kg)0.425; whereas glass yttrium-90 microspheres
were dosed based on infused liver volume: activity (GBq) = nominal target dose (Gy) × liver
mass for planning target volume (kg)/50.17 The prescribed dose was administered into the
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proper hepatic artery for bilobar treatment, left or right hepatic artery for unilobar. Two
consecutive treatments within 8 weeks were considered as sequential treatment.16,18
Postradiation Treatments
The subsequent treatments patients received after RE were recorded, including sorafenib,
transarterial chemoradioembolization, bland embolization, and liver transplantation.
Postradiation Toxicities
Clinical and laboratory adverse events were noted either during regular visits or through
patient reports within 90 days after RE treatment. Toxicities were graded according to the
National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE)
v4.0.19
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Statistics

Author Manuscript
Author Manuscript

Patients were stratified into 3 classes according to the ALBI formula previously described:
ALBI score = (log10 bilirubin [µmol/L] × 0.66) + (albumin [g/L] × −0.0852). ALBI grades
1, 2, and 3 were stratified as follows: ALBI score ≤ − 2.60 (ALBI grade 1), > −2.60 to ≤
−1.39 (ALBI grade 2), and > −1.39 (ALBI grade 3).7 Patients’ baseline characteristics
among 3 ALBI groups were presented. Owing to baseline characteristics required for receipt
of RE (eg, most patients’ total bilirubin < 2 mg/dL), only 3 patients were ALBI grade 3 and
were excluded from the following statistical analysis. We compared patients’ baseline
characteristics between ALBI grade 1 and 2 groups using Wilcoxon rank sum test for
continuous variables and χ2 test for categorical variables. Toxicities among different ALBI
grades were listed and compared using Fisher exact test. OS was evaluated by Kaplan-Meier
survival analysis. Medians and 95% confidence intervals (CI) were also presented. Utilities
of C-P class and ALBI grade as prognostic indicators were compared using log-rank test and
C-index which is, when outcome is time-event, a generalization of the area under the
receiver-operating characteristic curve. C-index measures the degree of discrimination: the
higher C-index, the higher discrimination.20 P value < 0.05 was considered statistically
significant. Univariate and multivariate Cox regression analyses were performed to look for
potential prognosticators cooperating with ALBI grade. Significant factors in univariate
regression analysis (P < 0.05) and factors of interest (ALBI grade, BCLC, and C-P class)
were taken into backward multivariate regression analysis (elimination level = 0.10). Only
factors with P values < 0.10 would stay in the final model because the sample size was
small. To better interpret their influence on mortality in univariate and multivariate Cox
regression analyses, certain continuous variables (AST, ALT, and AFP) were dichotomized
into low levels and higher levels according to their medians as cutoffs. All statistical
analyses were performed using SAS University Edition for Windows version (SAS Institute
Inc., Cary, NC) and R packages survival and compare C available on CRAN at http://cran.rproject.org.
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RESULTS
Descriptive Characteristics
A total of 117 HCC patients (median age 65.6 y old, 24 females, 93 males) who underwent
RE were included. According to ALBI grade classification, patients were divided into 3
groups: ALBI grade 1 (n = 49, 41.9%), ALBI grade 2 (n = 65, 55.6%), and ALBI grade 3 (n
= 3, 2.6%). All patients had similar baseline characteristics except ALT, AST, albumin,
bilirubin, ascites, INR, and C-P class (Table 1). According to C-P classification, patients
were classified as C-P class A (n = 100, 85.5%) and C-P class B (n = 17, 14.5%). According
to BCLC classification, patients were classified as BCLC stage A (n = 15, 12.8%), BCLC
stage B (n = 53, 45.3%), and BCLC stage C (n = 49, 41.9%).
Grade 2/3 and Grade 4/5 Toxicities
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Toxicities among 3 ALBI grades are listed in Table 2. There were 9 (7.7%) grade 2/3
adverse events and 8 (6.8%) grade 4/5 adverse events overall. Among those 8 grade 4/5
adverse events, 4 patients died from corresponding adverse events with 90 days (2 from
hepatic bleeding, 2 from hepatic failure). Among 3 ALBI grades, there was no significant
difference of grade 2/3 adverse events (P = 0.79), grade 4/5 adverse events (P = 0.57), or
total adverse events (P = 0.63).
OS
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ALBI revealed 2 classes with different prognoses for patients treated with RE. Patients with
ALBI grade 1 had an improved survival over ALBI grade 2 (P = 0.01, Kaplan-Meier curves
shown in Fig. 1) with median survival time of 16.7 months (95% CI, 12.3–56.9 mo)
compared with those with ALBI grade 2 who demonstrated a median survival of 9.8 months
(95% CI, 7.3–13.2 mo). The C-index for ALBI was 0.581. Meanwhile, no significant
difference in OS was observed between C-P class A and C-P class B (P = 0.11, KaplanMeier curves shown in Fig. 1) for which C-P class A demonstrated a median survival time of
13.2 months (95% CI, 9.7–15.7 mo) and C-P class B had a median survival of 10.4 months
(95% CI, 3.1–14.0 mo). The C-index for C-P was 0.545. There were significant differences
observed in OS between BCLC stage A and B (P = 0.02) and between BCLC stage A and C
(P < 0.01), but no significant differences observed in OS between BCLC stage B and C
(BCLC stage B: 13.0 mo; 95% CI, 8.1–15.6 mo; BCLC stage C: 10.4 mo; 95% CI, 7.2–13.8
mo; P = 0.28; C-index for BCLC 0.575). However, the median survival time of BCLC stage
A was not reached because of its low patient number and highly censored observation
number.
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Survival was stratified stepwise by C-P class, and then by ALBI grade or C-P score. For C-P
class A patients, 2 non-overlapping groups of ALBI grade 1 and 2 were revealed (P = 0.03;
C-index 0.572; Kaplan-Meier curves shown in Fig. 2). Median survival for ALBI grade 1
was 16.7 months; 95% CI, 12.3–56.9 months; whereas median survival for ALBI grade 2
was 10.8 months; 95% CI, 7.6–13.8 months. In contrast, C-P score 5 versus 6 had no
significant difference in terms of OS (P = 0.11; C-index = 0.545; Kaplan-Meier curves
shown in Fig. 2). Median survival for C-P score 5 was 14.5 months; 95% CI, 11.9–25.0
months; whereas C-P score 6 was 9.8 months; 95% CI, 7.6–15.0 months. For C-P class B
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patients, neither ALBI grade nor C-P score was able to discriminate subgroups with different
OS (P= 0.57 and 0.17, respectively).
Patients were stratified by BCLC stage first, then survival was compared between C-P class
and ALBI grade. Within each BCLC stage, neither C-P class nor ALBI grade distinguished
the survival time except that OS of C-P class A and B revealed a significant difference in
patients with BCLC stage C (P = 0.01; median of C-P class A: 12.3 mo, median of C-P class
B: 4.0 mo).
Univariate Cox regression analysis suggested that ALBI grade, BCLC, AFP, ALT, AST,
tumor volume percentage, and portal vein invasion were correlated with OS (P values <
0.05) (Table 3). On multivariate analysis, ALBI grade, BCLC, and ALT remained survival
prognosticators (P values < 0.10) (Table 4).

Author Manuscript

DISCUSSION
Our data revealed that ALBI grade had a superior ability to discriminate the prognosis of
HCC patients treated with RE, whereas C-P class was not able to clearly predict for OS. The
degree of discrimination by ALBI grade was better than C-P class both graphically and on
formal statistical analysis. The C-index for ALBI grade was slightly greater than that for C-P
class.
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In a recent study by Hickey et al,21 765 HCC patients treated with RE and
chemoembolization were independently divided into ALBI grade 2 and grade 3 with a
significant survival difference. The majority of patients in the study were C-P class B and
were stratified into 2 groups according to ALBI grade. In contrast, our patients generally had
preserved hepatic function with a normal total bilirubin and C-P class A classification at the
onset of treatment. Most of patients in the present study were successfully stratified by
ALBI grade within C-P class A. This demonstrates the versatility of ALBI grade
discrimination across both C-P class A and C-P class B patients. On the basis of our
outcome and the Hickey et al, outcome together, ALBI grade is a promising prognostic
factor that can be used widely in HCC patients treated with RE.
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C-P class includes 3 parameters that do not directly contribute to ALBI grade—INR, ascites,
and encephalopathy. However, distributions of INR and ascites were correlated with ALBI
grade. The relationship of ALBI grade with encephalopathy was limited by the low rates of
encephalopathy in this study; all 5 patients with encephalopathy had an ALBI score of 2 but
this did not reach statistical significance (P = 0.07). These results attest to the overlap of
hepatic function parameters (ascites, INR, encephalopathy) as prognosticators. Although
ALBI grade is composed only of albumin and bilirubin, it had a good capacity to reveal the
impact of liver function on survival time. It therefore may be preferred to avoid the
subjectivity of characterizing ascites and encephalopathy, which are sources of potential
error in the C-P system.
Liver function and tumor burden are 2 different factors that impact OS. These 2 factors are
also correlated, and patients with high tumor burden may have resulting decline in liver
function in excess of baseline hepatic dysfunction. In the multivariate analysis, tumor
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volume failed to independently predict OS. On the contrary, ALT which also suggests liver
function demonstrated its prognostic ability. Further studies with detailed causes of death
might uncover whether the mortality is associated with liver function failure or tumor
burden.
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Another prognostic factor is BCLC stage which has been commonly used to stratify and
select HCC patients for different therapeutic strategies.22 BCLC staging consists of
performance status, C-P score, tumor size, number of tumors, vascular invasion, nodal
spread, and extrahepatic metastases. BCLC stage includes both liver function and tumor
burden simultaneously, and helps to define treatments that are indicated for the patient. By
the definition, BCLC stage A (early stage), stage B (intermediate stage), and stage C
(advanced stage) share the same live function characteristic—C-P class A or B. However, as
we reported earlier, C-P class was not able to clearly predict for OS. ALBI grade might be a
promising substitute of C-P class in BCLC stage.
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Patients with ALBI grade 2 had the highest rate of adverse events (18.4%). Even though no
statistically significant difference of overall adverse events was found between different
ALBI grades, a higher ALBI grade seemed to show a higher number of liver-related
complications. As for CTCAE grade 2/3 liver-related complications, patients with ALBI
grade 1 presented fewer than ALBI grade 2 complications (n = 1 encephalopathy vs. n = 4
total including encephalopathy and ascites). High-grade liver-related complications (CTCAE
grade 4/5) were less frequent in patients with ALBI grade 1 than ALBI grade 2 (n = 1
hepatic failure vs. n = 6 total including hyperbilirubinemia, hepatic failure, and hepatic
bleeding). A larger population with a more robust analytical power to examine the
relationship between ALBI grade and liver-related complications would be useful for future
study.
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This study included patients receiving health care in 2 large medical centers, which ensured
high quality of follow-up, comprehensiveness of analysis factors, and consensus of data
(tested in Table 1). We analyzed a novel and promising predictor that is more objective than
the conventional C-P class. Our data provided a supplement to the results reported by
Hickey and colleagues who stratified between ALBI grade 2 and 3, but were unable to
illustrate differences between survivals for ALBI grade 1 and 2, and between these 2 groups
within C-P class A. Our finding of 2 distinct subpopulations (ALBI grade 1 and 2) within CP class A with different OS correlates with the findings of Johnson et al in their initial
discussion of the ALBI grade. More importantly, we addressed how the ALBI grade
performs in comparison with C-P score within a given C-P class. Johnson and colleagues did
not have access to C-P scores, and therefore could not answer this question. We found that
even though C-P score 5 and 6 seemed to graphically stratify the survival curves of C-P class
A, this difference was not statistically significant. However, ALBI grade successfully
demonstrated this capacity and revealed a higher discrimination degree than C-P score did
within C-P class A patients.
Because of the criteria of patients inclusion for RE (total bilirubin < 2 mg/dL), this study
was limited by the small proportion of C-P class B patents (n = 17, 14.5%) and ALBI grade
3 patients (n = 3, 2.6%), which set a barrier for the analysis of patients with poor liver
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function. Patients mostly had well-compensated cirrhosis (C-P class A, n = 100, 85.5%)
which might compromise the discrimination ability of C-P class. In addition, as a
consequence of a small sample size in each category, ALBI grade failed to break down the
survival in any subgroups stratified by BCLC stage. The same reason was considered to
explain why ALBI failed to demonstrate a P value < 0.05 (P value = 0.06) in multivariate
analysis.

Author Manuscript

In summary, ALBI grade is an objective prognosticator for liver function and has shown
survival discrimination of HCC patients treated with RE that is superior to C-P class. Our
study delineates the ability of ALBI grade to discriminate 2 subpopulations within C-P class
A. ALBI grade is a promising indicator for predicting the prognosis of patients with HCC;
therefore, it can play a role in guiding treatment options including RE. Further research
incorporating ALBI grade into an existing staging system might give rise to a more concise
and robust prediction system.
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FIGURE 1.

Author Manuscript

Overall survival in months after radioembolization stratified by albumin-bilirubin (ALBI)
grade (P = 0.01; C-index between ALBI grade 1 and 2 = 0.581) and Child-Pugh class (P =
0.11; C-index = 0.545).
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FIGURE 2.

Author Manuscript

Child-Pugh (C-P) class A patient survival in months for radioembolization according
albumin-bilirubin (ALBI) (P = 0.03; C-index = 0.572) and C-P score (P = 0.11; C-index =
0.545).
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Yes

Biopsy-proven (n [%])

Resin-based microspheres

Yes

Metastases (n [%])

SIRT type (n [%])

Yes

Range

Percentage
Yes

Median

Tumor volume (%)

Vascular invasion (n [%])

Yes

Cirrhosis (n [%])

Bilobar (n [%])

Yes

Encephalopathy (n [%])

15 (30.6)

28 (58.3)

7 (14.3)

17 (34.7)

19 (38.8)

1–74

16

33 (67.4)

0

2 (4.1)

0.95–1.36

Range
Yes

1.09

0.2–1.8

Range
Median

0.5

3.7–4.8

Range
Median

4.1

16–201

Range
Median

52

8–223

Range
Median

44

2.6–205,981.3

Range
Median

42.0

38–85

Range
Median

69

40 (81.6)

Median

Medical center 2

9 (18.4)

36 (73.5)

Male
Medical center 1

13 (26.5)

ALBI Grade 1

Female

Ascites (n [%])

INR

Bilirubin (mg/dL)

Albumin (g/dL)

AST (IU/L)

ALT (IU/L)

AFP (ng/mL)

Age (y)

Site (n [%])

Sex (n [%])

Parameter

Author Manuscript

Characteristics

20 (30.8)

36 (56.3)

8 (12.5)

26 (40.0)

34 (52.3)

1–84

21

53 (81.5)

5 (7.7)

19 (29.2)

0.80–1.77

1.15

0.2–2.2

0.9

2.6–4.1

3.5

25–365

88

15–287

69

4.7–151,806.0

190.9

36–90

63

50 (76.9)

15 (23.1)

54 (83.1)

11 (16.9)

ALBI Grade 2

0

0

0

0

1 (33.3)

1–11

6

3 (100)

2 (66.7)

2 (66.7)

1.25–1.65

1.35

1.5–2.6

1.6

1.9–2.6

2.4

45–235

156

41–165

128

8.1–921.1

18.6

60–69

64

3 (100)

0

3 (100)

0

ALBI Grade 3

Author Manuscript

Baseline Characteristics

0.99

0.86

0.78

0.56

0.15

0.38

0.08

0.07

< 0.001

0.02

0.0001

< 0.0001

< 0.01

0.04

0.08

0.057

0.54

0.21

P*
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C-P class (n [%])

BCLC stage (n [%])

Radiation activity (GBq)

Subsequent treatment after radioembolization (n [%])

1 (2.0)

Bland embolization

49 (100)
0

B

21 (42.9)

C
A

8 (16.3)
20 (40.8)

B

Range
A

2.38
0.87–7.73

Median

4 (8.2)

7 (14.3)

Liver transplant

9 (18.4)

TACE

24 (49.0)

Single administration
Sorafenib

25 (51.0)

Sequential administration

14 (21.5)

51 (78.5)

28 (43.1)

31 (47.7)

6 (9.2)

0.77–8.80

3.24

6 (9.2)

1 (1.5)

7 (10.8)

12 (18.5)

42 (64.6)

23 (35.4)

45 (69.2)

ALBI Grade 2

3 (100)

0

0

2 (66.7)

1 (33.3)

1.75–3.91

3.31

1 (33.3)

0

0

0

3 (100)

0

3 (100)

ALBI Grade 3

< 0.001

0.49

0.18

1.00

1.00

0.57

0.99

0.09

P*

AFP indicates a-fetoprotein; ALBI, albumin-bilirubin; ALT, alanine transaminase; AST, aspartate transaminase; BCLC, Barcelona Clinic Liver Cancer; C-P, Child-Pugh; INR, international normalized ratio;
SIRT, selective internal radiation therapy; TACE, transarterial chemoembolization.

P-values was computed by comparing ALBI grade 1 and grade 2 only, while grade 3 was removed due to limited number (n = 3).

*
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Treatment approach (n [%])

34 (69.4)

Glass microspheres
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ALBI Grade 1
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1
3 (6.1)

Mild encephalopathy

Grade 2/3 total (n [%])

1

Hepatic failure (encephalopathy)

12 (18.4)

6 (9.2)

2

2

0

0

2

6 (9.2)

1

1

1

3

ALBI Grade 2

ALBI indicates albumin-bilirubin; AST, aspartate transaminase.

2 (4.1)

0

Hepatic bleeding

5 (10.2)

1

Lymphopenia

Grade 4/5 total (n [%])

0

AST

Total (n [%])

0

Bilirubin > 10

Grade 4/5

1

1

Gastric antrum ulcer

Groin hematoma

0

Ascites

Grade 2/3

ALBI Grade 1

0

0

0

0

0

0

0

0

0

0

0

0

ALBI Grade 3

Author Manuscript

Adverse Event

17 (14.5)

8 (6.8)

3

2

1

0

2

9 (7.7)

2

2

2

3

Total

0.63

0.57

0.79

P
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Toxicity Event
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Univariate Cox Regression Analysis

Author Manuscript

Hazard
Ratio

95% Confidence
Interval

Sex

0.72

0.40–1.29

0.27

Age (y)

1.01

0.99–1.03

0.43

ALBI grade 2 vs. 1

1.78

1.12–2.84

0.01

BCLC stage B vs. A

2.85

1.10–7.35

0.03

BCLC stage C vs. A

3.72

1.46–9.48

< 0.01

Child-Pugh class

1.68

0.89–3.19

0.11

Tumor volume (%)

4.87

1.57–15.04

< 0.01

Portal vein invasion yes vs. no

1.63

1.02–2.57

0.04

AST > 80 vs. ≤ 80 (IU/L)

1.91

1.21–3.03

< 0.01

ALT > 63 vs. ≤ 63 (IU/L)

1.72

1.10–2.72

0.02

AFP > 144 vs. ≤ 144 (ng/mL)

1.79

1.14–2.83

0.01

Characteristics

P

AFP indicates α-fetoprotein level; ALBI, albumin-bilirubin; ALT, alanine transaminase; AST, aspartate transaminase; BCLC, Barcelona Clinic
Liver Cancer.
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TABLE 4
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Multivariate Backward Cox Regression
Analysis Characteristics

Hazard Ratio

P

ALBI grade 2 vs. 1

1.62

0.06

BCLC B vs. A

3.17

0.03

BCLC C vs. A

4.10

0.01

ALT > 63 vs. ≤ 63 (IU/L)

1.67

0.046

Elimination level = 0.10.
AFP indicates a-fetoprotein level; ALBI, albumin-bilirubin; ALT, alanine transaminase; AST, aspartate transaminase; BCLC, Barcelona Clinic
Liver Cancer.
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